a developer of patient-specific expanded cellular therapies for use in the treatment of patients with diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NDVSX | 20.24 | 0.33 | +1.66% |
MFS New Discovery Value R2 | |||
PYVAX | 19.81 | 0.16 | +0.81% |
Payden Equity Income Adviser | |||
MPRSX | 9.95 | 0.05 | +0.51% |
MassMutual Strat Emerg Mkts R4 | |||
RIRCX | 72.70 | 0.28 | +0.39% |
American Funds Capital Income Bldr R3 | |||
GMAZX | 15.12 | -0.01 | -0.07% |
GMO International Opportunistic Val IV |
A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.
Ticker / NAME | Correlation To VCEL | 1D Price Change % | ||
---|---|---|---|---|
VCEL | 100% | +4.23% | ||
VCYT - VCEL | 52% Loosely correlated | +1.67% | ||
BEAM - VCEL | 46% Loosely correlated | +6.23% | ||
ACLX - VCEL | 41% Loosely correlated | +3.69% | ||
PGEN - VCEL | 40% Loosely correlated | -0.03% | ||
CRBU - VCEL | 40% Loosely correlated | +2.02% | ||
More |